Skip to main content
Venus Medtech (Hangzhou) Inc. logo

Venus Medtech (Hangzhou) Inc. — Investor Relations & Filings

Ticker · 2500 ISIN · CNE100003PJ8 HKEX Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-06-05 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2500

About Venus Medtech (Hangzhou) Inc.

http://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. is an innovation-driven medical device company specializing in the research, development, manufacturing, and commercialization of transcatheter solutions for structural heart diseases. The company focuses on bioprosthetic heart valves, establishing a comprehensive pipeline that addresses aortic, pulmonary, mitral, and tricuspid valve diseases. Its product portfolio includes transcatheter aortic valve replacement (TAVR) solutions, and it is committed to addressing unmet demand in TPVR and TMVR. The company also develops solutions for hypertension, such as renal artery denervation ablation, and related surgical accessory products. Its products are commercialized globally, reaching over 60 countries and regions across Asia, Europe, and the Americas.

Recent filings

Filing Released Lang Actions
(1) 2024 ANNUAL REPORT (2) WORK REPORT OF THE BOARD FOR 2024 (3) WORK REPORT OF THE SUPERVISORY COMMITTEE FOR 2024 (4) PROFIT DISTRIBUTION PLAN FOR 2024 (5) RE-APPOINTMENT OF AUDITORS FOR 2025 (6) RE-
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a shareholder circular for the company’s 2024 Annual General Meeting, containing the notice of meeting, resolutions to be voted on (including adopting the annual report, re-appointment of auditors, election of directors, profit distribution plan, share issuance/repurchase mandates, etc.), explanatory statements and a proxy form. It is sent to shareholders to solicit votes and provide information ahead of the AGM. It is not the full annual report itself, nor a regulatory filing announcement, but rather the pre-meeting information and proxy solicitation. Therefore it falls squarely under Proxy Solicitation & Information Statement (PSI).
2025-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025
Regulatory Filings Classification · 82% confidence The document is a structured monthly return (Form FF301) filed with the Hong Kong Stock Exchange detailing movements in authorized/issued share capital, share options, repurchases and treasury shares for the month ended 31 May 2025. It is not announcing an AGM, dividend, management change, earnings, or similar. Rather, it is a routine regulatory return under the Exchange Listing Rules. This does not represent an earnings release, proxy statement, or formal capital raising announcement, but is a general listing rule return, best fitting the fallback category “Regulatory Filings (RNS)”.
2025-06-04 English
(1) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS FOR THE THIRD SESSION OF THE BOARD&#x3b; AND (2) PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS FOR THE THIRD SESSION OF THE SUPERVISORY COMM
Board/Management Information Classification · 92% confidence The document is an announcement by Venus Medtech (Hangzhou) Inc. regarding the proposed re-election and appointment of directors and supervisors for the next board and supervisory committee term. It is a corporate governance disclosure of board membership changes (re-election and appointment of Directors and Supervisors). This fits the definition of a Board/Management Information filing (MANG).
2025-05-30 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2025
Regulatory Filings Classification · 85% confidence The document is a Hong Kong Exchange Listing Rule monthly return (Form FF301) reporting movements in authorised/registered share capital, issued shares, share options, and other share capital items for the month ended 30 April 2025. It is a recurring regulatory submission rather than a standalone announcement of a specific share issuance or buyback. It does not present an earnings summary, a proxy statement, or an investor presentation, nor is it the full annual or interim report. It is best classified as a general regulatory filing under “Regulatory Filings” (RNS).
2025-05-07 English
Notification Letter to Non-Registered Holders - Notice of Publication of 2024 Annual Report and Reply Form
Report Publication Announcement Classification · 91% confidence The document is a notification letter titled “Notice of Publication of 2024 Annual Report,” informing non-registered shareholders that the company’s 2024 Annual Report and related corporate communications have been published online and providing instructions for requesting printed copies. It does not contain the actual annual report financials but simply announces its availability and directs recipients to the company’s and HKEX websites. Under the “menu vs meal” rule, this constitutes a Report Publication Announcement rather than the report itself.
2025-04-29 English
Notification Letter to Registered Shareholders - Notice of Publication of 2024 Annual Report and Reply Form
Report Publication Announcement Classification · 95% confidence The document is a shareholder notification letter informing registered shareholders of the publication of the 2024 Annual Report, providing links to English and Chinese versions on the HKEX and company websites and instructions for obtaining printed copies. It does not contain the actual annual report financial content but merely announces its availability and outlines the arrangement for electronic dissemination and reply form. This matches the definition of a Report Publication Announcement (RPA) rather than the full Annual Report (10-K) or any other category.
2025-04-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.